Omnipod® System: Learn the results from a 1-year study among adults with Type 1 diabetes.

Study title: Improved Glycemic Control Following Transition to the Omnipod® System in Adults with Type 1 Diabetes 1

Study design:

  • Multicenter, retrospective electronic health record study in the US.                                                  
  • 156 adults with type 1 diabetes (≥18 years of age) initiated therapy with Omnipod® System after either MDI or CSII with a tubed insulin pump.                                                                   
  • The primary endpoint was a change in A1C from the time of transition (baseline) to 12 months following initiation of the tubeless insulin pump                                                                  
Results:

In this study, the use of the tubeless insulin pump over 12 months was associated with significant improvement in HbA1c.*

*Baseline HbA1c = 8.1%, 12-months post-Omnipod initiation HbA1c = 7.8%; p < 0.007.

Please share your contact information with us to get access to the publication.

View the Publication

1. Mehta S, Tinsley L, Kruger D, et al. Improved glycemic control following the transition to tubeless insulin pump therapy in adults with type 1 diabetes. Published by Clinical Diabetes Journal, December 2020.

Important Safety Information: The Omnipod® Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. The Omnipod® System has been tested and found to be safe for use with the following U-100 insulin: Novolog®, Humalog®, Fiasp®, Admelog® or Apidra®. Refer to the Omnipod® Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.